Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
positive crawled date : 2022 - 05 - 20 save search
Live Nation Moves To Paid Internship Program And Receives 15,000 Applicants For 50 College Associate Positions
Published: 2022-05-20 (Crawled : 15:20) - livenationentertainment.com
LYV | $89.65 -0.49% -0.67% 1.4M
|
Consumer Services
|
| O: -0.14%
H: 2.11%
C: -1.21%
nation program positive
ClearPoint Neuro Congratulates Partner PTC Therapeutics on Receiving Positive CHMP Opinion for Gene Therapy
Published: 2022-05-20 (Crawled : 15:00) - biospace.com/
CLPT | $5.32 -3.27% -3.19% 59K
|
Health Technology
|
| O: 3.37%
H: 14.61%
C: 9.89%
chmp therapeutics positive therapy
ClearPoint Neuro Congratulates Partner PTC Therapeutics on Receiving Positive CHMP Opinion for Gene Therapy to Treat AADC Deficiency
Published: 2022-05-20 (Crawled : 14:00) - globenewswire.com
CLPT | $5.32 -3.27% -3.19% 59K
|
Health Technology
|
| O: 3.37%
H: 14.61%
C: 9.89%
chmp therapeutics positive therapy
Eiger Receives Positive CHMP Opinion for Zokinvy as a Treatment for Hutchinson-Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies
Published: 2022-05-20 (Crawled : 13:00) - prnewswire.com
EIGR | $1.725 -1.45% 140K
|
Health Technology
|
| O: 3.14%
H: 1.88%
C: -1.88%
treatment chmp zokinvy positive
Karyopharm and Menarini Group Receive Positive CHMP Opinion for NEXPOVIO® (selinexor) for the Treatment of Patients with Refractory Multiple Myeloma
Published: 2022-05-20 (Crawled : 13:00) - prnewswire.com
KPTI | $1.09 0.91% 1.2M
|
Health Technology
|
| O: 6.65%
H: 0.0%
C: 0.0%
nexpovio treatment chmp positive group
PTC Therapeutics Receives Positive CHMP Opinion for Upstaza™ for the Treatment of AADC Deficiency
Published: 2022-05-20 (Crawled : 12:20) - prnewswire.com
PTCT | News S | $25.21 -0.79% -0.87% 560K
|
Health Technology
|
| O: 1.96%
H: 1.95%
C: -1.52%
treatment chmp therapeutics positive
BridgeBio Pharma Affiliate Phoenix Tissue Repair Announces Positive Results from Phase 2 Trial of PTR-01, a Protein Replacement Therapy for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Published: 2022-05-20 (Crawled : 12:00) - globenewswire.com
BBIO | $25.03 -1.69% -1.76% 1.5M
|
Health Technology
|
| O: 3.42%
H: 2.83%
C: 2.7%
ptr-01 treatment pharma trial positive therapy
Gainers vs Losers
| 61% | 39% |
Top 10 Gainers
BOF | $2.08 77.78% 39.06% 110M
|
BHIL | $0.1793 -4.37% 19.24% 340K
|
Agriculture, Forestry, Fishing ...
UMAC | $1.48 -1.33% 14.87% 20K
|
CI | $352.28 -0.11% 13.53% 2
|
Health Services
CIG.C | $2.89 -1.37% 12.8% 2.3K
|
n/a
MTH | $154.69 -2.21% 12.68% 450K
|
Consumer Durables
HCP | News | $31.41 7.75% 11.26% 1.2M
|
BMTX 4 | $1.545 0.98% 10.03% 2.5K
|
Information
TAL | $12.26 0.57% 9.22% 12M
|
Consumer Services
ASXC | $0.243 -2.41% 7.0% 1.1M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.